Basic/Translational Science Survey Section: Kidney Cancer

Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study.

European urology·2025

Adrenal imaging features and associated pathologic diagnoses: A contemporary, longitudinal analysis.

Surgery·2025

Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.

Urologic oncology·2025

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.

The Lancet. Oncology·2025

Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.

Urologic oncology·2024

Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.

The Lancet. Oncology·2024

Quantitative core-level tumor burden and grading in MRI-targeted vs. systematic prostate biopsy: A within-patient paired analysis.

Urologic oncology·2026

Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer.

Urologic oncology·2026

Predicting long-term metastatic risk after radical prostatectomy: Adding Genomic Prostate Score, grade group, and cribriform size to unfavorable histology burden translates into minimal incremental discrimination.

Urologic oncology·2026

Trans-perineal prostate biopsy-Prognostic factors for "no prostate tissue" in biopsy cores.

Urologic oncology·2026

Benign but burdensome: Complications and management of benign prostatic hyperplasia during active surveillance of prostate cancer in a large cohort.

Urologic oncology·2026

Cancer-specific mortality in high-risk or very high-risk prostate cancer patients treated with focal therapy vs. radical prostatectomy.

Urologic oncology·2026

Targeting CXCR2 in Nociceptive Sensory Neurons Offers Novel Therapeutic Potentials for Postoperative Pain.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Letter to "NR1D2 Knockdown Alleviates Myocardial Infarction Through Nrf2 Signaling Pathway Activation".

Cardiovascular drugs and therapy·2026

The Protective Effect of Astragalus Polysaccharides Against Cisplatin‑Induced Pulmonary Epithelial Cell Injury: An Integrated Network Toxicology and In Vitro Validation.

Cell biochemistry and biophysics·2026

H2AFY2 suppresses exhaustion and enhances antitumor activity of CAR-T cells through transcriptional and epigenetic modifications.

Cancer immunology research·2026

ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Inhibiting Ribosomal RNA Synthesis in C. elegans Protects Against Reductive Stress During de novo Fatty Acid Synthesis Deficiency.

Genetics·2026

Related Experiment Videos

Basic/Translational Science Survey Section: Kidney Cancer

Related Concept Videos

Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study.

Adrenal imaging features and associated pathologic diagnoses: A contemporary, longitudinal analysis.

Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.

Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.

Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.

Quantitative core-level tumor burden and grading in MRI-targeted vs. systematic prostate biopsy: A within-patient paired analysis.

Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer.

Predicting long-term metastatic risk after radical prostatectomy: Adding Genomic Prostate Score, grade group, and cribriform size to unfavorable histology burden translates into minimal incremental discrimination.

Trans-perineal prostate biopsy-Prognostic factors for "no prostate tissue" in biopsy cores.

Benign but burdensome: Complications and management of benign prostatic hyperplasia during active surveillance of prostate cancer in a large cohort.

Cancer-specific mortality in high-risk or very high-risk prostate cancer patients treated with focal therapy vs. radical prostatectomy.

Targeting CXCR2 in Nociceptive Sensory Neurons Offers Novel Therapeutic Potentials for Postoperative Pain.

Letter to "NR1D2 Knockdown Alleviates Myocardial Infarction Through Nrf2 Signaling Pathway Activation".

The Protective Effect of Astragalus Polysaccharides Against Cisplatin‑Induced Pulmonary Epithelial Cell Injury: An Integrated Network Toxicology and In Vitro Validation.

H2AFY2 suppresses exhaustion and enhances antitumor activity of CAR-T cells through transcriptional and epigenetic modifications.

ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.

Inhibiting Ribosomal RNA Synthesis in C. elegans Protects Against Reductive Stress During de novo Fatty Acid Synthesis Deficiency.

Related Experiment Videos

Basic/Translational Science Survey Section: Kidney Cancer

Related Concept Videos

Related Articles